Entering text into the input field will update the search result below

Immunohistochemistry (IHC) Market Development And Business Intelligence

Sep. 22, 2021 1:42 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2014

#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology

Summary

  • Major factors influencing the growth of the market.
  • Leading players & Business Strategies.
  • Geographic Overview.

Market growth influenced due to following factors-

  • Increasing incidence and prevalence of cancer.
  • Technological advancements in IHC.
  • The availability of reimbursement for IHC tests.

Global market size-

According to research report global immunohistochemistry market is projected to reach USD 2.7 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 6.6% during the forecast period.

Leading Players-

The global IHC market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), PHC Holding Corporation (Japan), Biocare Medical, LLC. (US), and Merck KGaA (Germany).

For details Download PDF Brochure Here

Geographic Overview -

North America accounted for the largest share of the Immunohistochemistry Market, followed by Europe in 2019. The growth in this regional market can be attributed to the presence of major players operating in the market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.